All In Biotech

Drug Trial Radar · NCT07103174

A Study of MG-K10 Humanized Monoclonal Antibody Injection in Subjects With Atopic Dermatitis

A Phase II Clinical Study on the Efficacy and Safety of MG-K10 Humanized Monoclonal Antibody Injection in Patients With Moderate to Severe Atopic Dermatitis

Last checked: Nov 20, 2026Latest source record: Aug 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

60

Actual

Start

Jun 30, 2025

Primary completion

Mar 9, 2026

Study completion Apr 29, 2026

Sponsor

Sponsor type
Industry
First posted
Aug 5, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a multicenter, randomized, double-blind, parallel controlled phase II study. It is planned to include approximately 60 subjects with moderate to severe atopic dermatitis(AD) to evaluate the efficacy and safety of MG-K10 monotherapy in adult patients with moderate to severe AD, and to observe PK characteristics, PD effects and immunogenicity.

Conditions

  • Atopic Dermatitis (AD)

Interventions

  • MG-K10/PlaceboDrug

    To ensure blinding, 4 mL of placebo will be administered subcutaneously at Weeks 4, 12 and 20., for a total of 3 doses.

  • MG-K10/PlaceboDrug

    To ensure blinding,an additional 2 mL of placebo will be administered subcutaneously at Weeks 4, 8, 12, 16 and 20.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The percentage of subjects reaching EASI-75 at 24 weeks of treatmentTime frame: 24 weeks
  2. The percentage of subjects who achieved the IGA score standard at 24 weeks of treatmentTime frame: 24 weeks

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Tower 5,No.34,Chunxiao Road No.122 Pudong District, Shanghai, 201203.p R. china

    Shanghai, Shanghai Municipality, China

  • Hangzhou First People's Hospital

    Zhejiang, 杭州, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.